Xofigo is named as an intervention in 5 current clinical trials in our Spain, Sweden, Brazil, Australia, UK, USA, India, China, Germany, France, Poland, Austria, Turkey, Canada, Japan, South Korea, Taiwan, Israel, Netherlands, Mexico, Italy, Belgium, Switzerland and Norway registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is AstraZeneca (1). The most-studied condition is Metastatic Castration-resistant Prostate Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Xofigo. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Quantitative Unified Assessment of Novel Triplet therapy and Unconventional Maintenance with Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial
2026-525550-11-00 · Male Urogenital Diseases
|
Phase 2 | Authorised | Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard | Spain |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
5 current trials in our Spain, Sweden, Brazil, Australia, UK, USA, India, China, Germany, France, Poland, Austria, Turkey, Canada, Japan, South Korea, Taiwan, Israel, Netherlands, Mexico, Italy, Belgium, Switzerland and Norway registers name Xofigo (also registered as Radium-223) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 5 trials are recruiting: 1 with sites in Spain, 2 with sites in Sweden, 1 with sites in Brazil, 1 with sites in Australia, 1 with sites in UK, 1 with sites in USA, 1 with sites in India, 1 with sites in China, 1 with sites in Germany, 1 with sites in France, 1 with sites in Poland, 1 with sites in Austria, 1 with sites in Turkey, 1 with sites in Canada, 1 with sites in Japan, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Israel, 1 with sites in Belgium, 1 with sites in Switzerland and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AstraZeneca (1), Memorial Sloan Kettering Cancer Center (1), Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) and Peter MacCallum Cancer Centre, Australia (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Xofigo works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Xofigo works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Xofigo (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.